Business
Correction Directorate Change & Audited accounts
Correction Directorate Change & Audited accounts.
About this update from Valirx Plc
[{"type":"text","content":"\n \n \n RNS Number : 2681P\n ValiRx PLC\n 08 June 2020\n \n \n \n \n The following amendment has been made to the 'Directorate Change & Audited accounts extension' announcement released on 8 June 2020 at 07:00 a.m. under RNS No 1854P.\n \n \n \n \n \n The announcement should have stated the number of shares held by Dr Suzanne Dilly as 166,668 instead of 1,666,668 as previously disclosed. \n \n \n \n \n \n All other details remain unchanged.\n \n \n \n \n \n The full amended text is shown below.\n \n \n \n \n \n \n \n \n VALIRX PLC\n \n \n (\"ValiRx\", the \"Company\" or the \"Group\")\n \n \n \n \n \n Directorate Change and Extension of Reporting deadline for publication of audited accounts for\n \n \n year to 31 December 2019\n \n \n \n \n \n \n London, UK\n \n , 8June 2020: ValiRx (AIM:VAL) is pleased to announce that, further to the announcement of 1 May 2020, Dr Suzanne Dilly has been appointed as a director of the Company with immediate effect with the title Chief Executive Officer.\n \n \n \n \n \n Following her appointment, the board comprises:-\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Dr Suzanne Dilly\n \n \n \n \n Chief Executive Officer\n \n \n \n \n \n \n Mr Gerry Desler\n \n \n \n \n Chief Financial Officer\n \n \n \n \n \n \n Mr Kevin Alexander\n \n \n \n \n Non-executive Director\n \n \n \n \n \n \n Mr Martin Lampshire\n \n \n \n \n Non-executive Director\n \n \n \n \n \n \n \n \n As announced on 27 May 2020 Dr Kevin Cox will be appointed as Non-executive Chairman, following completion of normal regulatory due diligence, which is expected to be completed in the coming weeks.\n \n \n \n \n \n The Company does not intend to make any further changes to the board in 2020.\n \n \n \n \n \n Extension of deadline for publication of audited accounts to year to 31 December 2019\n \n \n \n \n \n Due to the current COVID-19 outbreak, the Company will be unable to post its annual audited accounts to shareholders for the year to 31 December 2019 by the 30 June 2020 deadline pursuant to AIM Rule 19.\n \n \n \n \n \n Further to the guidance provided by AIM Regulation in \"Inside AIM\" on 26 March 2020, the Company requested an additional period of up to three months to publish its annual audited accounts for the year e...